Floatz Rating
B61/100
Confidence
Indicative
Sponsor
University of Utah
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
46Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06194929CT.gov Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma | — | Recruiting | — | — | — |
NCT05767879CT.gov (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma | — | Unknown | — | — | — |
NCT05026983CT.gov Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases | — | Recruiting | — | — | — |
NCT04221438CT.gov Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement | — | Terminated | — | — | — |
NCT04511013CT.gov A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | — | Recruiting | — | — | — |
NCT03543969CT.gov Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma | — | Active Not Recruiting | — | — | — |
NCT02910700CT.gov Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cutaneous Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Encorafenib (this asset) | University of Utah | P2 | B · 61 |
| Alpha-Interferon | MIPO Clinic | P3 | BBB |
| TIL | City of Hope Medical Center | P2 | BBB |
| Dacarbazine | Linnaeus Therapeutics, Inc. | P3 | BBB |
| Tyrosinase Peptide | University of Southern California | P3 | BBB |
| Cis-Diamminedichloroplatinum Ii | MIPO Clinic | P3 | BBB |
| Nivestim | Vastra Gotaland Region | P3 | BB |
| Multi-Epitope Melanoma Peptide Vaccine | Craig L Slingluff, Jr | P2 | BB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
+42 more in the Cutaneous Melanoma cohort
Other indications for Encorafenib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colon Carcinoma | — | P3 | BB · 68 |
| Colon Adenocarcinoma | — | P2/3 | BB · 67 |
| Colorectal Cancer | — | P2 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Encorafenib in Cutaneous Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/encorafenib-cutaneous-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →